conversation
FW In Conversation: Mineralys CEO Jon Congleton on Reviving Hypertension Innovation and Lorundrostat’s Best-in-Class Potential
Mineralys Therapeutics; Jon Congleton; lorundrostat; aldosterone synthase inhibitor; hypertension treatment; FW In Conversation